Cristian Massacesi to Lead Unified R&D Organization Designed to Accelerate Pipeline Momentum, Effective January 1, 2027
Bristol Myers Squibb (NYSE: BMY) today announced that Cristian Massacesi will lead a unified, end-to-end Research & Development organization, effective January 1, 2027. As part of this planned transition, Robert Plenge will remain with Bristol Myers Squibb in an advisory capacity through March 2027 to support a seamless transition before departing the company.
Effective January 1, 2027, the unified R&D organization will bring together Bristol Myers Squibb’s scientific and clinical expertise as one organization, strengthening collaboration from discovery through development. By combining the strengths of its teams, BMS aims to advance its pipeline with greater speed, sharper focus and a shared commitment to delivering for patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.